Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026
Impact of spirulina-enriched yogurt-like dessert on blood pressure in overweight individuals with high cardiometabolic risk: results from in vitro studies and a randomized, placebo-controlled clinical trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Papakonstantinou Emilia, Lympaki Foteini, Savvidou Aggeliki, Dalaka Eleni, Georgiopoulos Georgios, Giannoglou Marianna, Karatzi Kalliopi, Chaloulakou Stavroula, Delialis Dimitrios, Keramida Kalliopi, Zampelas Antonis, Katsaros George, Theodorou Georgios
Аннотация
BACKGROUND AND AIM: Spirulina (Arthrospira platensis) contains peptides with angiotensin-I converting enzyme (ACE) inhibitory activity, suggesting possible antihypertensive effects. However, food-matrix interactions may alter peptide release or bioactivity. This study evaluated (i) the in-vitro ACE-inhibitory activity of <3 kDa peptide fractions after simulated gastrointestinal digestion of spirulina biomass (SB) and a spirulina-enriched yogurt-like dessert (YSB), and (ii) the effects of daily YSB consumption on blood pressure (BP) and vascular function in overweight/obese adults with elevated cardiometabolic risk.
METHODS AND RESULTS: SB, YSB, and control yogurt (YC) underwent simulated gastrointestinal digestion and <3 kDa fractions were assessed for ACE-inhibition. In a randomized, placebo-controlled, parallel, clinical trial, adults (n = 64 completers; 32 per group) consumed YSB (4 g/day spirulina) or isoenergetic YC for 8 weeks, followed by 4 weeks of observation. Peripheral BP, central BP, pulse wave velocity (PWV), and augmentation index (AIx) were measured at baseline, week 8, and week 12. In-vitro, SB and YC exhibited ACE-inhibitory activity, while YSB did not. Clinically, no significant group∗time interactions were observed for BP, PWV, or AIx. Results were unchanged in sensitivity analyses excluding antihypertensive-treated participants and in subgroups with elevated baseline BP.
CONCLUSIONS: SB exhibited ACE-inhibitory activity in vitro; however, incorporation into a yogurt-like matrix abolished this effect. Daily YSB consumption did not lower BP or improve vascular markers. Findings highlight the critical role of food-matrix interactions in functional food development.
CLINICALTRIALS: gov: NCT06114563.
METHODS AND RESULTS: SB, YSB, and control yogurt (YC) underwent simulated gastrointestinal digestion and <3 kDa fractions were assessed for ACE-inhibition. In a randomized, placebo-controlled, parallel, clinical trial, adults (n = 64 completers; 32 per group) consumed YSB (4 g/day spirulina) or isoenergetic YC for 8 weeks, followed by 4 weeks of observation. Peripheral BP, central BP, pulse wave velocity (PWV), and augmentation index (AIx) were measured at baseline, week 8, and week 12. In-vitro, SB and YC exhibited ACE-inhibitory activity, while YSB did not. Clinically, no significant group∗time interactions were observed for BP, PWV, or AIx. Results were unchanged in sensitivity analyses excluding antihypertensive-treated participants and in subgroups with elevated baseline BP.
CONCLUSIONS: SB exhibited ACE-inhibitory activity in vitro; however, incorporation into a yogurt-like matrix abolished this effect. Daily YSB consumption did not lower BP or improve vascular markers. Findings highlight the critical role of food-matrix interactions in functional food development.
CLINICALTRIALS: gov: NCT06114563.